E
PYXS icon

Ergoteles’s Pyxis Oncology PYXS Stock Holding History

Ergoteles’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-36,415
Closed -$87K – 1897
2022
Q2 		$87K Buy
+36,415
New +$96.9K ﹤0.01% 1527

Other funds holding PYXS

LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Ergoteles's PYXS Position: Q3 2022 in Review

Ergoteles sold out of Pyxis Oncology (PYXS) in Q3 2022, closing a stake of 36,415 shares — an estimated $87K sold.

Ergoteles first reported a position in PYXS in Q2 2022 and held it in 1 quarter. The position peaked at $87K in Q2 2022. 38 funds tracked by Wall St. Rank hold PYXS as of Q3 2022.

  • Ergoteles reported no remaining Pyxis Oncology position as of Q3 2022 after selling out during the quarter.
  • Ergoteles sold 36,415 Pyxis Oncology shares in Q3 2022, an estimated $87K.
  • Ergoteles first reported a position in Pyxis Oncology in Q2 2022 and held it in 1 quarter.
  • Ergoteles's Pyxis Oncology position peaked at $87K in Q2 2022.
  • 38 funds tracked by Wall St. Rank held Pyxis Oncology as of Q3 2022.

Based on Ergoteles's 13F filing for Q3 2022, filed 14 Nov 2022.